Comparative analysis of plasma pTau217, NfL and eight modifiable risk scores for 11-year dementia prediction in the HUNT Study
In the HUNT Study, plasma pTau217 emerged as a strong predictor of 11-year dementia risk, with eight modifiable risk scores providing statistically significant but marginal improvements in discrimination and complementary value for risk stratification, while NfL offered no additional predictive benefit.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
The human brain is a vast, intricate landscape that can slowly erode over time, leading to a condition known as dementia, where memory and thinking skills fade. For decades, scientists have searched for ways to predict this decline before the first symptoms appear, hoping to intervene early enough to slow or stop the damage. Two main approaches have emerged to help with this prediction. The first involves looking at a person's lifestyle and health history, such as their diet, exercise habits, and blood pressure, to calculate a risk score. The second involves taking a blood sample to look for tiny biological signals, or biomarkers, that indicate the brain is already undergoing changes associated with Alzheimer's disease. While both methods show promise, it has remained unclear whether they offer unique insights or if they simply tell the same story in different ways. Understanding whether these tools work better together than alone is crucial for developing effective strategies to prevent dementia in the future.
In a large-scale study involving thousands of people in Norway, researchers set out to compare these two approaches directly. They followed a group of nearly 4,000 participants over a period of roughly eleven years, starting when the participants were in their late sixties on average. At the beginning of the study, the team collected blood samples to measure two specific proteins: one called pTau217, which is a sign of the sticky protein clumps found in Alzheimer's disease, and another called NfL, which acts as a marker for general nerve damage in the brain. At the same time, the researchers gathered detailed information about the participants' lives to calculate eight different dementia risk scores. These scores combined various factors, from high cholesterol and depression to social isolation and physical activity, to estimate each person's likelihood of developing dementia.
The researchers then watched to see who developed dementia over the next decade. When they analyzed the results, the blood test for pTau217 stood out as the most powerful single predictor. People with higher levels of this protein in their blood at the start of the study were significantly more likely to develop dementia eleven years later. The test was particularly accurate for women and for those carrying a specific genetic variant known to increase Alzheimer's risk. In contrast, the other blood marker, NfL, did not add any meaningful value to the prediction once the pTau217 levels were already known. It failed to improve the ability to distinguish between those who would develop dementia and those who would not.
The study also examined how well the lifestyle risk scores performed on their own and when combined with the blood test. The risk scores did provide useful information, showing that people with higher scores were indeed at greater risk. However, their ability to predict the future was not as strong as the pTau217 blood test. When the researchers combined the blood test with the risk scores, the prediction accuracy improved only slightly, but the improvement was statistically real. This suggests that while the blood test captures the biological machinery of the disease, the risk scores capture the accumulated effect of a person's life choices and health history. The two tools appear to offer complementary information rather than redundant data.
Perhaps the most striking finding came from looking at how these factors worked together. The researchers grouped participants based on whether they had high or low risk scores and high or low levels of the pTau217 protein. They found a clear gradient of risk. People who had both a high-risk lifestyle profile and high levels of the protein were far more likely to develop dementia than those with low levels of both. In fact, those in the highest combined risk group were up to eleven times more likely to develop the disease than those in the lowest risk group. Interestingly, even among people with high levels of the protein, those who maintained a healthier lifestyle profile had a lower risk than those with poor lifestyle habits. This indicates that while the biological damage signaled by the protein is a strong warning sign, the cumulative effect of lifestyle factors still plays a significant role in whether that damage translates into clinical dementia.
The study also looked at how age and gender influenced these results. The predictive power of the blood test and risk scores was generally stronger in women than in men. It was also stronger in people who were sixty-five or older at the start of the study compared to those who were younger. For the younger group, the ability to predict dementia was lower, likely because the disease is less common in that age range and the window for observation was shorter. Despite these variations, the pattern held true across the board: the blood protein was the strongest indicator, and the lifestyle scores added a small but meaningful layer of detail.
This research provides a clearer picture of how we might one day screen for dementia risk. It suggests that a blood test for pTau217 could serve as a highly effective early warning system, identifying individuals whose brains are already changing. However, it also shows that knowing a person's lifestyle history adds valuable context. The combination of a biological snapshot and a life-history review offers a more complete view of risk than either method could provide alone. While the blood test tells us about the current state of the brain's pathology, the risk scores remind us that the path to dementia is paved with many years of health decisions. For now, these findings point toward a future where doctors might use both tools to identify who needs the most urgent attention and to tailor prevention strategies that address both biology and lifestyle.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.